168 related articles for article (PubMed ID: 37587253)
21. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
[TBL] [Abstract][Full Text] [Related]
22. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
23. Characterizing and predicting ccRCC-causing missense mutations in Von Hippel-Lindau disease.
Serghini A; Portelli S; Troadec G; Song C; Pan Q; Pires DEV; Ascher DB
Hum Mol Genet; 2024 Jan; 33(3):224-232. PubMed ID: 37883464
[TBL] [Abstract][Full Text] [Related]
24. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
25. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH; Kaelin WG
Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
[TBL] [Abstract][Full Text] [Related]
26. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
27. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
29. An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
Gossage L; Pires DE; Olivera-Nappa Á; Asenjo J; Bycroft M; Blundell TL; Eisen T
Hum Mol Genet; 2014 Nov; 23(22):5976-88. PubMed ID: 24969085
[TBL] [Abstract][Full Text] [Related]
30. Whole-exome sequencing and immunohistochemistry findings in von Hippel-Lindau disease.
Guo X; Gao L; Hong X; Guo D; Di W; Wang X; Xu Z; Xing B
Mol Genet Genomic Med; 2019 Sep; 7(9):e880. PubMed ID: 31317677
[TBL] [Abstract][Full Text] [Related]
31. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
[TBL] [Abstract][Full Text] [Related]
32. High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells.
Zhu S; Ding W; Chen Y; Wang W; Xu R; Liu C; Liu X; Deng H
Genomics Proteomics Bioinformatics; 2022 Aug; 20(4):657-669. PubMed ID: 33647481
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family.
Yuan P; Sun Q; Liang H; Wang W; Li L; Wang Y; Deng H; Lai L; Chen X; Zhou X
Cancer Biol Ther; 2016 Jun; 17(6):599-603. PubMed ID: 27057652
[TBL] [Abstract][Full Text] [Related]
34. Independent Tumor Origin in Two Cases of Synchronous Bilateral Clear Cell Renal Cell Carcinoma.
Ji Z; Zhao J; Zhao T; Han Y; Zhang Y; Ye H
Sci Rep; 2016 Jul; 6():29267. PubMed ID: 27383411
[TBL] [Abstract][Full Text] [Related]
35. PBX1, EMCN and ERG are associated with the sub-clusters and the prognosis of VHL mutant clear cell renal cell carcinoma.
Wang H; Wang X; Xu L; Zhang J
Sci Rep; 2022 May; 12(1):8955. PubMed ID: 35624190
[TBL] [Abstract][Full Text] [Related]
36. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
37. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive characterization and building of National Registry of von Hippel-Lindau disease in Brazil.
Dallagnol TN; Da Cás E; Junior OR; Casali-da-Rocha JC
Mol Genet Genomic Med; 2023 Apr; 11(4):e2136. PubMed ID: 36625343
[TBL] [Abstract][Full Text] [Related]
39. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
40. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential
Mizutani K; Yokoi S; Sawada S; Sakamoto I; Kameyama K; Kamei S; Hirade K; Sugiyama S; Matsunaga K; Yamada T; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2022; 19(6):740-746. PubMed ID: 36316043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
